Tyrosine kinase inhibitors

A compound of Formula I

• or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
• Y is:
• S;
• Q is O or absent;
• R1 is (C1-C10)alkyl, substituted with Or(C═O)sNRaRb, wherein r and s are independently 0 or 1, and optionally substituted with one or more substituents selected from R7;
• R2 is selected from:
• 1) H,
• 2) Or(C1-C6)perfluoroalkyl,
• 3) OH,
• 4) CN,
• 5) halogen,
• 6) (C═O)rOs(C1-C10)alkyl,
• 7) (C═O)rOs(C2-C8)cycloalkyl,
• 8) (C═O)rOs(C2-C10)alkenyl,
• 9) (C═O)rOs(C2-C10)alkynyl,
• 10) (C═O)rOsaryl,
• 11) (C═O)rOsheterocyclyl, and
• 12) NRaRb,
• wherein r and s are independently 0 or 1, and said alkyl, cycloalkyl, alkenyl, alkynyl, aryl, and heterocyclyl is optionally substituted with one or more substituents selected from R7;
• R4 is H or (C1-C6)alkyl;
• R5 is selected from:
• 1) H,
• 2) SO2Rc,
• 3) (C═O)rRc, wherein r is 0 or 1, and
• 4) cO2Rc;
• R6 is selected from:
• 1) aryl,
• 2) (C3-C8)cycloalkyl
• 3) (C1-C10)alkyl,
• 4) (C2-C8)alkenyl,
• 5) (C2-C8)alkynyl, and
• 6) heterocyclyl, wherein r and s are independently 0 or 1, and said aryl, cycloalkyl, alkyl, alkenyl, alkynyl and heterocyclyl optionally substituted with one or more substituents selected from R7;
• R7 is selected from:
• 1) Or(C═O)sNRaRb,
• 2) (CO)rOsaryl,
• 3) (C═O)rOs-heterocyclyl,
• 4) halogen,
• 5) OH,
• 6) oxo,
• 7) O(C1-C3)perfluoroalkyl,
• 8) (C1-C3)perfluoroalkyl,
• 10) CHO,
• 11) CO2H,
• 12) CN, and
• 13) (C3-C8)cycloalkyl, wherein r and s are independently 0 or 1, and said aryl, heterocyclyl and cycloalkyl are optionally substituted with one or more substituents selected from Rd;
• Ra and Rb are independently selected from:
• 1) H,
• 2) (C═O)r(C1-C10)alkyl,
• 3) (C═O)r(C3-C6) cycloalkyl,
• 4) S(O)2Rc,
• 5) (C═O)rheterocyclyl,
• 6) (C═O)raryl, and
• 7) CO2Rc, wherein r is 0 or 1 and said alkyl, cycloalkyl, heterocyclyl, and aryl optionally substituted with one or more substituents selected from Rd, or Ra and Rb are taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from Rd;
• Rc is (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, or heterocyclyl;
• Rd is selected from:
• 1) (C═O)rOs(C1-C10)alkyl, wherein r and s are independently 0 or 1, optionally substituted with up to three substituents selected from OH, (C1-C6)alkoxy, halogen, CN, oxo, N(Re)2 and S(O)2Rc,
• 2) Or(C1-C3)perfluoroalkyl,
• 3) (C0-C6)alkylene-S(O)mRc, wherein m is 0, 1, or 2,
• 4) oxo,
• 5) OH,
• 6) halo,
• 7) CN,
• 8) (C3-C6)cycloalkyl, optionally substituted with up to three substituents selected from OH, (C1-C6)alkoxy, halogen, CN, axe, N(Re)2, and S(O)2Rc,
• 9) (C0-C6)alkylene-aryl, optionally substituted with up to three substituents selected from Rc,
• 10) (C0-C6)alkylene-heterocyclyl, optionally substituted with up to three substituents selected from Re,
• 11) (C0-C6)alkylene-N(Re)2,
• 12) C(O)Rc,
• 13) CO2Rc,
• 14) C(O)H, and
• 15) CO2H;
• and
• Re is H, (C1-C6)alkyl, aryl, heterocyclyl, (C3-C6)cycloalkyl or S(O)2Rc;
• and as used herein, the term “heterocycle” is a 5- to 10-membered aromatic or nonaromatic, monocyclic or bicyclic, heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of O, N and S.